Clinical Trial Search

Primary: Objectively Measured Physical Activity of at Least Moderate Intensity (MVPA) by the Actigraph GT3X+ — 10; 21; 57.5; 23 minutes/week — p=.04

Primary: Percentage of Participants Free From MR (Magnetic Resonance) Scan-related Complications — 100 percentage of participants

Primary: Change in Background Parenchymal Uptake (BPU) on Molecular Breast Imaging (MBI) — 0.0; -12 percent change in BPU

Primary: Number of Participants With Change in Number of Risky Sexual Partnerships — 32; 24; 88; 36 Participants

Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale, Version 5 (ADHD-RS-5) Total Score — -11.04; -10.38 units on a scale

Primary: Program Enrollment Rate (%) — 6.1 percentage of invitees

Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale, Version 5 (ADHD-RS-5) Total Score — -9.17; -11.34 units on a scale

Primary: Decrease in Frequency of Nightmares Using the Sleep-50 Questionnaire — 2.25; 2.75 score on a scale

Primary: Number of Adverse Events — 51; 45 Number of events in treatment group

Primary: Number of Patients With Cutaneous Bacterial Load After Surgery — 0; 18; 21; 1 Participants — p=<0.05

Primary: Usability of the MKit WebApp as Assessed by the 10-item System Usability Scale — 64.36 score on a scale

Primary: Number of Responders 24-hours Post-ketamine Infusion — 3; 1; 3; 2 participants

Primary: Percentage of Patients With At Least One Adenoma — 63; 68 Participants

Primary: Percentage of Subjects Ready for Discharge in Each Group at 30 Minutes Post Procedure — 26; 44 Participants

Primary: Residualized Change in Counts of Unprotected Anal Intercourse at 3 Months — .10; -.09 Res. Change in Counts of UAI at 3 months